Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | UGT2B17 | O75795 | 2/20 | 0.46 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.42 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151022 | 1.00 | OPRL1 (0.51) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL30997127 | 1.00 | OPRL1 (0.51) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL1508536 | 1.00 | OPRL1 (0.51) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL12014020 | 0.90 | UGT2B17 (0.58) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL5752195 | 0.89 | UGT2B17 (0.51) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL15494638 | 0.84 | POLL (0.41) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL3630215 | 0.84 | POLL (0.41) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL9277764 | 0.84 | POLL (0.41) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL30038859 | 0.83 | UGT2B17 (0.42) | OPRL1KCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL13517902 | 0.80 | POLL (0.44) | OPRL1KCNH2OPRM1POLLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180208560-A1 | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-26 | — | — | US | disclosed |
| WO-2018109642-A1 | N-ARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| US-20180148411-A1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-31 | — | — | US | disclosed |
| EP-3074375-B1 | NEW INDANYLOXYPHENYLCYCLOPROPANECARBOXYLIC ACIDS | BOEHRINGER INGELHEIM INT (DE) | 2018-04-04 | — | — | EP | disclosed |
| EP-2046714-B1 | Cyclopentane derivatives as antiglaucoma agents | ALLERGAN INC (US) | 2015-12-09 | — | — | EP | disclosed |
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| CN-103649101-A | Catalyst and process for preparing same | BOREALIS AG | 2014-03-19 | — | — | CN | disclosed |
| US-8569349-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8338637-B2 | Glaucoma; prostaglandin receptor modulators; cyclopentyl compounds such as 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid | ALLERGAN, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8309739-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2012-11-13 | — | — | US | disclosed |
| WO-2007020377-A2 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007020377-A2 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| EP-1250342-B1 | BRIDGED METALLOCENE COMPOUNDS AS OLEFIN-POLYMERIZATION CATALYSTS | POLIMERI EUROPA SPA (IT) | 2006-06-28 | — | — | EP | disclosed |
| US-6984703-B1 | Bridged metallocene compounds as olefin-polymerization catalysts | POLIMERI EUROPA S.P.A. (IT) | 2006-01-10 | — | — | US | disclosed |
| WO-2005103055-A1 | PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2005-11-03 | — | — | WO | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| EP-1250342-A1 | BRIDGED METALLOCENE COMPOUNDS AS OLEFIN-POLYMERIZATION CATALYSTS | Polimeri Europa S.p.A. (IT) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001040238-A1 | BRIDGED METALLOCENE COMPOUNDS AS OLEFIN-POLYMERIZATION CATALYSTS | POLIMERI EUROPA S.P.A. (IT) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | OPRL1 125/4885KCNH2 211/4885ADRA2A 11/4885 |
| US-20180208560-A1 | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | GPR119, GPR55, GPR65 | OPRL1 89/4885KCNH2 1340/4885ADRA2A 141/4885 |
| US-20180148411-A1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GPR119, GPR65, GPR55 | OPRL1 103/4885KCNH2 1765/4885ADRA2A 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.